Literature DB >> 16242072

A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells.

Stefania Merighi1, Annalisa Benini, Prisco Mirandola, Stefania Gessi, Katia Varani, Edward Leung, Stephen MacLennan, Pier Giovanni Baraldi, Pier Andrea Borea.   

Abstract

Hypoxia-inducible factor-1 (HIF-1) is a key regulator of genes crucial to many aspects of cancer biology. The purine nucleoside, adenosine, accumulates within many tissues under hypoxic conditions, including that of tumors. Because the levels of both HIF-1 and adenosine are elevated within the hypoxic environment of solid tumors, we investigated whether adenosine may regulate HIF-1. Here we show that, under hypoxic conditions (< 2% O2), adenosine upregulates HIF-1alpha protein expression in a dose-dependent and time-dependent manner, exclusively through the A3 receptor subtype. The response to adenosine was generated at the cell surface because the inhibition of A3 receptor expression, by using small interfering RNA, abolished nucleoside effects. A3 receptor stimulation in hypoxia also increases angiopoietin-2 (Ang-2) protein accumulation through the induction of HIF-1alpha. In particular, we found that A3 receptor stimulation activates p44/p42 and p38 mitogen-activated protein kinases, which are required for A3-induced increase of HIF-1alpha and Ang-2. Collectively, these results suggest a cooperation between hypoxic and adenosine signals that ultimately may lead to the increase in HIF-1-mediated effects in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242072      PMCID: PMC1502026          DOI: 10.1593/neo.05334

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  61 in total

1.  Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line.

Authors:  S Merighi; K Varani; S Gessi; E Cattabriga; V Iannotta; C Ulouglu; E Leung; P A Borea
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells.

Authors:  B C Suh; T D Kim; J U Lee; J K Seong; K T Kim
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

3.  A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study.

Authors:  Stefania Gessi; Katia Varani; Stefania Merighi; Elena Cattabriga; Valeria Iannotta; Edward Leung; Pier Giovanni Baraldi; Pier Andrea Borea
Journal:  Mol Pharmacol       Date:  2002-02       Impact factor: 4.436

4.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.

Authors:  H Zhong; K Chiles; D Feldser; E Laughner; C Hanrahan; M M Georgescu; J W Simons; G L Semenza
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

Review 5.  HIF-1: mediator of physiological and pathophysiological responses to hypoxia.

Authors:  G L Semenza
Journal:  J Appl Physiol (1985)       Date:  2000-04

6.  C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Authors:  A C Epstein; J M Gleadle; L A McNeill; K S Hewitson; J O'Rourke; D R Mole; M Mukherji; E Metzen; M I Wilson; A Dhanda; Y M Tian; N Masson; D L Hamilton; P Jaakkola; R Barstead; J Hodgkin; P H Maxwell; C W Pugh; C J Schofield; P J Ratcliffe
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

Review 7.  Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection.

Authors:  J Linden
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 8.  Hypoxia inducible factor as a cancer drug target.

Authors:  Sarah J Welsh; Garth Powis
Journal:  Curr Cancer Drug Targets       Date:  2003-12       Impact factor: 3.428

9.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.

Authors:  H Zhong; A M De Marzo; E Laughner; M Lim; D A Hilton; D Zagzag; P Buechler; W B Isaacs; G L Semenza; J W Simons
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

Review 10.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

View more
  27 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

Review 2.  Adenosine receptors in wound healing, fibrosis and angiogenesis.

Authors:  Igor Feoktistov; Italo Biaggioni; Bruce N Cronstein
Journal:  Handb Exp Pharmacol       Date:  2009

3.  Adenosine Kinase Deficiency Increases Susceptibility to a Carcinogen.

Authors:  Rkia El-Kharrag; Randy Owen; Detlev Boison
Journal:  J Caffeine Adenosine Res       Date:  2019-03-14

Review 4.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

5.  Human brain endothelial cells are responsive to adenosine receptor activation.

Authors:  Jeffrey H Mills; Leah Alabanza; Babette B Weksler; Pierre-Olivier Couraud; Ignacio A Romero; Margaret S Bynoe
Journal:  Purinergic Signal       Date:  2011-02-17       Impact factor: 3.765

Review 6.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

Review 7.  Investigational A₃ adenosine receptor targeting agents.

Authors:  Balázs Koscsó; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Expert Opin Investig Drugs       Date:  2011-04-02       Impact factor: 6.206

8.  Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.

Authors:  Peter Büchler; Howard A Reber; James S Tomlinson; Oliver Hankinson; Georgis Kallifatidis; Helmut Friess; Ingrid Herr; Oscar J Hines
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

9.  Embryonic caffeine exposure induces adverse effects in adulthood.

Authors:  Christopher C Wendler; Melissa Busovsky-McNeal; Satish Ghatpande; April Kalinowski; Kerry S Russell; Scott A Rivkees
Journal:  FASEB J       Date:  2008-12-16       Impact factor: 5.191

Review 10.  Adenosine receptors and cancer.

Authors:  P Fishman; S Bar-Yehuda; M Synowitz; J D Powell; K N Klotz; S Gessi; P A Borea
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.